Page 51 - Read Online

Lo Re et al. J Cancer Metastasis Treat 2019;5:81 I http://dx.doi.org/10.20517/2394-4722.2019.30 Page 7 of 8

REFERENCES
1. Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate
from embryonic hematopoiesis and promote tumor progression. Immunity 2017;47:323-38.
2. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for
polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
3. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, et al. A unique subset of CD4+CD25highFoxp3+ T cells secreting IL-
10 and TGF-β1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007;13:4345-54.
4. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
5. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, et al. Increased survival in pancreatic cancer with nabpaclitaxel plus
gemcitabine. N Engl J Med 2013;369:1691-703.
6. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
New Engl J Med 2011;364:1817-25.
7. Cullis J, Siolas D, Avanzi A, Barui S, Maitra A, et al. Macropinocytosis of nabpaclitaxel drives macrophage activation in pancreatic
cancer. Cancer Immunol Res 2017;5:182-90.
8. Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, et al. Low-dose gemcitabine depletes regulatory T cells and improves survival
in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 2013;133:98-107.
9. Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol 2004;5:617-25.
10. Lutgendorf SK, Lamkin DM, DeGeest K, Anderson B, Dao M, et al. Depressed and anxious mood and T-cell cytokine producing
populations in ovarian cancer patients. Brain Behav Immun 2008;22:890-900.
11. Lee IM, Wolin KY, Freeman SE, Sattlemair J, Sesso HD. Physical activity and survival after cancer diagnosis in men. J Phys Act Health
2014;11:85-90.
12. Lee IM, Sesso HD, Oguma Y, Paffenbarger RS Jr. Physical activity, body weight, and pancreatic cancer mortality. Br J Cancer
2003;88:679-83.
13. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced
cancer. N Engl J Med 2012;366:2455-65.
14. Hidalgo M, Epelbaum R, Wolpin BM, Stemmer M, Geva R, et al. A Phase 2a Trial to Assess the Safety and Efficacy of BL-8040 and
Pembrolizumab in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC). Ann Oncol 2018;29: viii400-41.
15. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, et al. Physical activity, biomarkers, and disease outcomes
in cancer survivors: a systematic review. J Natl Cancer Inst 2012;104:815-40.
16. Woods JA, Davis JM, Smith JA, Nieman DC. Exercise and cellular innate immune function. Med Sci Sports Exerc 1999;31:57-66.
17. Zheng X, Cui XX, Huang MT, Liu Y, Wagner GC, et al. Inhibition of progression of androgen-dependent prostate LNCaP tumors to
androgen independence in SCID mice by oral caffeine and voluntary exercise. Nutr Cancer 2012; 64:1029-37.
18. Saxton JM, Scott EJ, Daley AJ, Woodroofe M, Mutrie N, et al. Effects of an exercise and hypocaloric healthy eating intervention on
indices of psychological health status, hypothalamic-pituitary adrenal axis regulation and immune function after early-stage breast cancer:
a randomised controlled trial. Breast Cancer Res 2014;16:R39.
19. Ellingsgaard H, Hojman P, Pedersen BK. Exercise and health - emerging roles of IL-6. Curr Opin Physiol 2019;10:49-54.
20. Zimmer P, Schenk A, Kieven M, Holthaus M, Lehmann J, et al. Exercise induced alterations in NK-cell cytotoxicity - methodological
issues and future perspectives. Exerc Immunol Rev 2017;23:66-81.
21. Koelwyn GJ, Wennerberg E, Demaria S, Jones LW. Exercise in regulation of inflammation-immune axis function in cancer initiation and
progression. Oncology (Williston Park) 2015;29:908-20.
22. Peake JM. Exercise-induced alterations in neutrophil degranulation and respiratory burst activity: possible mechanisms of action. Exerc
Immunol Rev 2002;8:49-100.
23. Betof AS, Lascola CD, Weitzel D, Landon C1, Scarbrough PM, et al. Modulation of murine breast tumor vascularity, hypoxia and
chemotherapeutic response by exercise. J Natl Cancer Inst 2015;107:djv040.
24. Almeida PW, Gomes-Filho A, Ferreira AJ, Rodrigues CE, Dias-Peixoto MF, et al. Swim training suppresses tumor growth in mice. J Appl
Physiol (1985) 2009;107:261-5.
25. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. Type, density, and location of immune cells within human colorectal
tumors predict clinical outcome. Science 2006;313:1960-4.
26. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the
immune landscape in human cancer. Immunity 2013;39:782-95.
27. Facciabene A, Motz GT, Coukos. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012;72:2162-
71.
28. Woods JA, Ceddia MA, Wolters BW, Evans JK, Lu Q, et al. Effects of 6 months of moderate aerobic exercise training on immune
function in the elderly. Mech Ageing Dev 1999;109:1-19.
29. Simpson RJ, Bigley AB, Agha N, Hanley PJ, Bollard CM, et al. Mobilizing immune cells with exercise for cancer immunotherapy. Exerc
Sport Sci Rev 2017;45:163-72.
30. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death.
Nat Med 2007;13:54-61.
31. Nickel T, Emslander I, Sisic Z, David R, Schmaderer C, et al. Modulation of dendritic cells and toll-like receptors by marathon running.
Eur J Appl Physiol 2012;112:1699-708.